MarginsXMarginsX
Home › Markets › Health Care › ENGN

enGene Therapeutics Inc. (ENGN)

ENGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.89
-21.58% on the day
Market cap
$126.7M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerENGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001980845
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inCanada

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
4.8 months
$41.0M cash at July 31, 2026
Share count, 1 year
+30.9%
2025-09-10 to 2026-09-02
Going-concern doubt
No
10-Q filed September 8, 2026
Insider net buying, 12 months
$10K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity and Going Concern In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued."
10-Q 2026-09-08
Cash and burn$41.0M cash; operating cash flow -$25.8M a quarter.Report 2026-07-31
Shares outstanding67,016,316 (2026-09-02); 51,191,771 a year earlier.Cover page 2026-09-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Montreal, CanadaPCAOB Form AP 2026-01-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $10K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-07-31
Not filed-$32.5M-$18.9M$41.0M$199KNeeds four quarters10-Q 2026-09-08
Q2 2026
2026-04-30
Not filed-$30.2M-$30.5M$29.8M$193KNeeds four quarters10-Q 2026-09-08
Q1 2026
2026-01-31
Not filed-$29.8M-$28.9M$36.6M$188KNeeds four quarters10-Q 2026-09-08
Q4 2025
2025-10-31
Not filed-$37.9M-$25.0M$50.2M$8.0MNeeds four quarters10-K 2025-12-22
Q3 2025
2025-07-31
Not filed-$29.0M-$25.6M$32.6M$5.4MNeeds four quarters10-Q 2026-09-08
Q2 2025
2025-04-30
Not filed-$25.8M-$22.9M$57.5M$3.6MNeeds four quarters10-Q 2026-09-08
Q1 2025
2025-01-31
Not filed-$24.6M-$25.7M$62.3M$1.7MNeeds four quarters10-Q 2026-09-08
Q4 2024
2024-10-31
Not filed-$15.3M-$19.6M$173.0M$699KNeeds four quarters10-K 2025-12-22

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-09
Latest annual report10-K/A2026-02-19
Latest quarterly / interim10-Q2026-09-08
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-05-08

Source: SEC EDGAR submissions feed, 272 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+37.7%
1 month+47.9%
3 months+42.6%
Year to date-73.3%
1 year-71.4%
From 52-week high-80.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
ENGNWenGene Therapeutics Inc. Warrants$0.2100

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
TARAProtara Therapeutics Inc.$2.38-5.93%$146.5M
HUMAHumacyte Inc.$0.5403-3.24%$150.1M
ZURAZura Bio Limited$1.08-12.90%$104.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier